Novel antipsoriatic fluidized spanlastic nanovesicles: In vitro physicochemical characterization, ex vivo cutaneous retention and exploratory clinical therapeutic efficacy
| Autor: | Maha Nasr, Maha H. Ragai, Riham I. El-Gogary, Enas Elmowafy |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male Skin Absorption Pharmaceutical Science Polysorbates 02 engineering and technology Pharmacology Administration Cutaneous 030226 pharmacology & pharmacy Synthetic retinoid 03 medical and health sciences Young Adult 0302 clinical medicine Tazarotene Psoriasis medicine Animals Humans Hexoses Skin Eucalyptol Chemistry Penetration enhancer Nicotinic Acids Middle Aged 021001 nanoscience & nanotechnology medicine.disease In vitro Nanostructures Rats Treatment Outcome Female Dermatologic Agents Nanocarriers 0210 nano-technology Psoriasis treatment Ex vivo medicine.drug |
| Zdroj: | International journal of pharmaceutics. 568 |
| ISSN: | 1873-3476 |
| Popis: | Tazarotene (TAZ) is a topical synthetic retinoid used in psoriasis treatment, however, it is extremely lipophilic and exhibits skin irritation. Research is in a state of continuous advancement in the field of nanocarriers fabrication, and in this regard, we investigated the formulation of novel topically oriented nanovesicles; representing a combination of spanlastics and penetration enhancer vesicles, to be termed (fluidized-SNs). TAZ-loaded fluidized SNs were physicochemically characterized, tested for ex vivo cutaneous retention, and the selected formulation was compared with the marketed product Acnitaz® regarding clinical antipsoriatic activity. The selected fluidized-SNs enriched with 1% cineole exhibited high entrapment for TAZ (76.19%), suitable size and zeta potential of 241.5 ± 5.68 nm and −36.10 ± 2.50 mV respectively, and retaining of stability after refrigeration storage for one month. As hypothesized, cineole enriched fluidized-SNs exhibited remarkable TAZ deposition amounting to a total of 81.51% in the different skin layers. Upon clinical assessment, the presented formulation displayed superior traits compared to the marketed product, in terms of dermoscopic imaging, morphometric analysis of psoriatic lesions, and statistical analysis of PASI scores. Results confirmed that the prepared novel fluidized spanlastics formulation holds great promise for the treatment of psoriasis, and its benefit should futuristically be investigated in other topical diseases. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect